MuGard regulatory update

Access Pharmaceuticals said China's State Food and Drug Administration (SFDA) approved a regulatory application from partner Rhei Pharmaceuticals Inc. (Hong Kong, China) for MuGard mucoadhesive oral rinse to treat oral mucositis (OM) in cancer patients. Access said MuGard is expected to be launched in the "next couple quarters." Rhei has rights to commercialize MuGard in China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam from Access under a 2008 deal. Additionally, Rhei granted Jian An Pharmaceuticals Ltd. (Shenzhen, China) an exclusive sublicense to commercialize MuGard in China and Taiwan. ...